Phaseline

Companies › Hanlim Pharm.

Hanlim Pharm.: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 4 Phase 3; Cardiovascular; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HL1113R1–Phase 3HypertensionDec 2028
HL1113R2–Phase 3HypertensionDec 2028
HL1113T1–Phase 3HypertensionDec 2028
HL1113T2–Phase 3HypertensionDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07552389HL1113T2Phase 3HypertensionCardiovascularDec 2028
NCT07552389HL1113T1Phase 3HypertensionCardiovascularDec 2028
NCT07552389HL1113R1Phase 3HypertensionCardiovascularDec 2028
NCT07552389HL1113R2Phase 3HypertensionCardiovascularDec 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

CeleCor Therapeutics MedTrace Pharma SPH Qingdao Growful Pharmacetical Trust Bio-sonics Liquidia Technologies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.